Photo by Mediamodifier / Unsplash. Illustrative stock photograph; no endorsement or medication use is implied.
By David L. Carpenter, BSN, RN
Evidence checked: November 1, 2026 (Medicare GLP-1 Bridge update); other evidence last checked October 22, 2026 | United States
A refill that suddenly costs more than you can afford can turn an ordinary pharmacy trip into a difficult decision. You may be wondering whether to appeal, switch medicines, pay out of pocket, or stop treatment. The most useful first step is to find out exactly what changed while asking your prescriber to help you plan for any gap.
This guide focuses on adults using Wegovy or Zepbound who face an insurance or affordability problem. It offers questions to ask and a way to organize the next steps. Your plan documents determine coverage; your prescriber and pharmacist should guide medication changes. A denial does not, by itself, tell you whether continuing treatment is medically appropriate.
Find out what the pharmacy rejection means
Ask the pharmacist for the exact rejection message. Then contact the insurer or pharmacy benefit manager using the number on your insurance card. Ask whether the problem is a missing or expired prior authorization, a formulary change, a benefit exclusion, a pharmacy restriction, or your share of the cost. A formulary is the plan’s list of covered medicines. Review the plan’s written coverage materials rather than relying only on the price at the register. [1]
If the answer is “not covered,” ask the representative to be more specific. Does the plan exclude this drug, exclude treatment for this purpose, or need more clinical information? Ask for the relevant policy and the effective date of any change. These questions help your clinician decide what to submit; they do not guarantee an exception.
Keep one record with the date, representative’s name, call reference number, and promised next step. Save the denial letter and pharmacy messages. Note the date of your last dose and how much medicine remains, so you and your prescriber can plan around your next due dose.
Ask about an exception or appeal
HealthCare.gov’s guidance describes Marketplace coverage, including drug exceptions and possible temporary access during review. Employer plans, especially self-funded plans, Medicare, and Medicaid may follow different rules. Ask which process applies to your plan and whether a transition refill is available. Your prescriber may need to explain why covered alternatives are unsuitable. [1,9]
For a denial under your insurance plan, rather than the Medicare Bridge described below, read the instructions for an internal appeal. An independent external review may also be available, depending on the plan and the type of denial. Follow the deadline in your notice. If a delay could seriously threaten your health, ask your clinician whether an expedited review is appropriate. An appeal challenges a decision; it does not promise that an excluded benefit will become covered. [2]
Make the request specific: “What information is missing, who needs to submit it, and where should it go?” Ask your clinician’s office who handles authorizations and whether they received the denial. You can also ask your employer’s benefits office to help identify the correct contact. Avoid sending the same incomplete request repeatedly without understanding why it failed.
Compare costs you can sustain
Manufacturer copay cards and self-pay offers are different programs. Commercial-insurance cards generally exclude government-program enrollees; self-pay offers have separate terms. Eligibility may depend on insurance, dose, formulation, and refill timing. Some plans do not count copay-card money toward your deductible. If yours does this, the card terms may bar you from using it; other plan arrangements can also affect eligibility. Read the exact program’s current terms; offers may change. [3,4,10]
Ask for the price of your actual prescription after any introductory offer ends. Paying cash does not automatically count toward your deductible or out-of-pocket limit. Some offers prohibit seeking reimbursement or submitting payments toward those limits. Confirm this before paying, and include any visits, membership fees, supplies, or shipping in your comparison. [4,10]
Bring a realistic spending limit to your prescriber. A useful question is: “If I cannot afford this medicine next month, what treatment options are appropriate for me?” The alternative may involve a different approved medicine or a revised care plan. Do not treat different drugs, doses, or delivery devices as interchangeable. Coverage and clinical suitability both need checking.
If you have Medicare
Since July 1, 2026, the temporary Medicare GLP-1 Bridge has offered eligible people with qualifying Medicare drug coverage certain weight-management medicines for $50 a month. These include Foundayo tablets, Wegovy injections and tablets, and Zepbound KwikPen, but not Zepbound vials or single-dose pens. The Bridge is scheduled to end December 31, 2027. See the current CMS program information and Medicare.gov covered-drug list (checked November 1, 2026). The payments do not count toward your Part D deductible or annual out-of-pocket limit. [12,13]
Your plan type and health criteria matter, and your prescriber must request approval. The Bridge operates outside the usual Part D benefit. It has no appeals process, but your prescriber can resubmit corrected or additional information. If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH (a type of fatty liver disease) with moderate-to-advanced liver scarring, or your medicine is prescribed to reduce major cardiovascular events, the Bridge does not apply. Your coverage request must go through your Part D plan instead; approval is not guaranteed, and a denial follows the Part D appeal process. A Bridge denial is different from a Part D plan denial. Call 1-800-MEDICARE (1-800-633-4227) to clarify which route applies. [12,13]
Plan a treatment gap before changing doses
Send your prescriber the medication name, formulation, current dose, last dose date, remaining supply, and expected length of the gap. Ask for written instructions covering what to do now and how to restart. Avoid independently stretching the interval between injections or improvising smaller doses to make a supply last.
For weekly Wegovy injection, the current U.S. label directs restarting dose escalation at a lower dosage after two or more consecutive missed doses to reduce gastrointestinal side effects. Its Medication Guide tells patients who miss two or more consecutive weeks to contact their prescriber about restarting. Have your prescriber select the dose. [5]
Wegovy tablets are taken daily: skip a missed tablet and take the next dose the following day, without an extra dose. Tablets and injections are not interchangeable milligram for milligram. Tablets also have separate fasting and timing instructions; ask your pharmacist to review them if your formulation changes. [5]
For one missed weekly Zepbound dose, the label allows taking it within four days, or 96 hours. After that, skip it and take the next scheduled dose. Keep at least three days, or 72 hours, between doses. This is not a universal restart schedule after several missed doses; ask your prescriber before resuming. [6]
If you have diabetes, ask about glucose monitoring and other medicines during the gap and restart, particularly insulin or sulfonylureas. Do not adjust them independently. Seek prompt medical care for persistent severe abdominal pain, repeated vomiting, or inability to keep fluids down. [5,6]
If you use oral hormonal contraception, Zepbound’s label calls for a non-oral method or added barrier protection for four weeks after starting and after each dose increase. Ask how this applies if restarting involves dose escalation. [6]
Understand what stopping research can and cannot tell you
In the STEP 1 extension, the group previously assigned semaglutide 2.4 mg regained, on average, about two-thirds of its earlier weight loss during the following year. The exploratory analysis included 327 selected trial completers across treatment groups; structured lifestyle support also stopped. Selection could affect the findings. Novo Nordisk funded the trial, and authors disclosed industry relationships, including manufacturer employment. This was not a study of a brief insurance gap. [7]
That result supports planning for ongoing care, but it cannot predict your weight change over a week or a month. It also does not establish what a specific person taking tirzepatide will experience. Regain should prompt a treatment discussion, not a conclusion that you failed.
Keep daily routines manageable
During the disruption, choose a few routines you can realistically maintain. For example, write down a simple grocery list, plan regular meals around your work schedule, and keep activity at a level that fits your health and abilities. If your care team has given you nutrition or fluid restrictions, continue to follow them.
These are practical ways to organize a difficult week, not a proven substitute for medication or a guarantee against regain. If hunger becomes harder to manage, report it to your care team. Agree on a follow-up date and decide together whether weight, symptoms, blood glucose, or other measures would be useful to track.
Be careful with cheaper online substitutes
FDA warns that unapproved GLP-1 products do not undergo its review for safety, effectiveness, and quality. Compounded products are not FDA-approved generics of Wegovy or Zepbound. FDA has received reports of dosing errors with compounded injectable semaglutide, including cases requiring hospitalization. [8]
Use a licensed prescriber and a state-licensed pharmacy, but remember that licensure does not make a compounded product FDA-approved. Avoid products sold as research chemicals or “not for human consumption.” If compounding is proposed, ask why an approved medicine cannot meet your medical needs and request clear product and dosing instructions. [8]
FDA reports that the national semaglutide and tirzepatide injection shortages are resolved. Its April 1, 2026 update explains restrictions on compounding products that are essentially copies of available approved drugs. The rules depend on the compounding circumstances; do not assume shortage-era availability still applies. Ask the prescriber and pharmacist to explain the current basis for the proposed product. [11]
A practical next call
You can tell your clinician’s office: “My next refill has been rejected or is unaffordable. My last dose was on [date], my dose is [dose], and I have [supply] left. Can you help identify the coverage problem and give me a plan if I miss treatment?”
Before ending the call, clarify who will contact the insurer, when you should expect an update, and whom to call if the next dose is due before the issue is resolved. You do not need to solve every insurance question before asking for clinical help.
A coverage interruption can require a change in treatment, but it does not have to mean losing contact with care. Work on access and the medical plan together, with costs you can sustain and restart instructions you understand.
Sources
1. HealthCare.gov. Getting prescription medications.
https://www.healthcare.gov/using-marketplace-coverage/prescription-medications/
2. HealthCare.gov. How to appeal an insurance company decision.
https://www.healthcare.gov/appeal-insurance-company-decision/appeals/
3. Novo Nordisk. Wegovy cost and coverage information and linked program terms.
https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
4. Eli Lilly. Zepbound savings and insurance options and program terms.
https://zepbound.lilly.com/savings
5. Novo Nordisk. Wegovy U.S. prescribing information and Medication Guide. Revised June 2026. Sections 2.4, 2.5 and 5; accessed October 22, 2026.
https://www.novo-pi.com/wegovy.pdf
6. Eli Lilly. Zepbound U.S. prescribing information and Medication Guide. Revised August 2026. Sections 2.3, 5, 7.2 and 8.3; accessed October 22, 2026.
https://pi.lilly.com/us/zepbound-uspi.pdf
7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–1564. doi:10.1111/dom.14725.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/
8. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
9. U.S. Department of Labor. Filing a claim for your health benefits.
https://www.dol.gov/agencies/ebsa/about-ebsa/our-activities/resource-center/publications/filing-a-claim-for-your-health-benefits
10. Novo Nordisk. Wegovy savings offer eligibility and terms.
https://www.novocare.com/eligibility/wegovy-savings-card.html
11. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. April 1, 2026 update.
https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
12. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: Information for Providers. Updated August 6, 2026; accessed October 22, 2026.
https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
13. Medicare.gov. Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month. Product No. 12234, June 2026; accessed October 22, 2026.
https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf
Leave a Reply